FDAsafety guidance66% confidence
FDA AP — BREZTRI AEROSPHERE (SUPPL)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA212122. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: BUDESONIDE, FORMOTEROL FUMARATE, GLYCOPYRROLATE.
Supporting Context
- Therapeutic area
- Endocrinology · Hypertension
- Sub-indication
- Hypertension
Related signal: FDA Accepts Application for BAXFENDY (BAXDROSTAT) from AstraZeneca